Clinical Evaluation of Platelet Concentrates Either in Plasma or in Additive Solution
Luis Larrea*, 1, Nelly Carpio2, Cristina Arbona3, María Angeles Soler1, Javier de la Rubia 2, Roberto Roig 1
Identifiers and Pagination:Year: 2008
First Page: 25
Last Page: 29
Publisher Id: TOHJ-2-25
Article History:Received Date: 10/03/2008
Revision Received Date: 02/04/2008
Acceptance Date: 04/04/2008
Electronic publication date: 11/4/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background and Objectives
Platelet concentrates (PC) obtained from Buffy-Coat (BC) may be diluted in a platelet additive solution (PAS). These PCs may reduce plasma-related adverse reactions. We have tried to assess the relationship between PAS PCs and adverse reactions.
Materials and Methods
During 6 months, patients treated with intensive chemotherapy, participated in a prospective study and were randomly assigned to receive, on a prophylactic basis, PCs in either plasma or PAS-2. Five iso-group BCs were pooled diluted in either plasma or PAS-2. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded.
Platelet increment, 1-hour platelet count, and corrected count increments (CCI) after transfusion in both groups were similar. There were more transfusion- dependent adverse reactions in plasma group.
Use of PAS-2 resulted in less transfusion related reactions; therefore, we recommend synthetic additive solutions to dilute PCs.